Health & Biotech Science journal Nature reveals decade-long remissions; sparks hope for curative potential of CAR-T treatment February 11, 2022 Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of cancer treatments? The latest research… Creso Pharma welcomes legendary Canadian founder, investing leader and CBD entrepreneur Bruce Linton February 10, 2022 Bruce Linton is now focused on building Creso into the kind of CBD giant his name has become synonymous with. Government backs Singular Health innovation with $305k R&D tax fund February 9, 2022 Special Report: Singular Health Group’s unique contribution to developing national technologies in the research fields of spinal and soft tissue… Morgans: This incredible Aussie medtech is trading at just ⅓ its real value February 9, 2022 Special Report: As the founder sets up shop stateside, brokers at Australia's biggest wealth manager are calling locally-listed Audeara a… ASX Health Stocks: dorsaVi gets ISO certification; Actinogen to begin Phase 2 trial February 9, 2022 Motion analysis device maker dorsaVi (ASX:DVL) has been awarded the internationally recognised ISO 27001 certification, verifying the data security standards… ASX Health Stocks: NeuroScientific gains on study news; FDA report gives Auscann a boost February 8, 2022 NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The… ASX Health Stocks: Resonance gets green light in US February 7, 2022 Medical imaging software Resonance Health (ASX:RHT) has received the green light in the US for its LiverSmart medical device. ASX Health Stocks: PIQ leaps 9pc on blood test results; Respiri gains 6pc on Wheezo order February 4, 2022 The ASX 200 Health Index (XHJ) and the benchmark ASX 200 are trading flat today. Proteomics advances on blood test… ASX Health Stocks: OncoSil up 15pc on German device funding; Starpharma expands to Middle East February 3, 2022 The ASX 200 Health Index (XHJ) has fallen by 1.26% at the time of writing, compared to the broader index… Creso Pharma stakes its claim of the multibillion US CBD market in landmark acquisition February 3, 2022 Special Report: The acquisition of Sierra Sage Herbs will propel Creso into the US CBD market, as it pursues further… Next» « Previous